[Abstract Only] Randomized Trial: Oral GLP-1 Receptor Agonist and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Peptide Innovation for Early Diabetes Treatment 6 – PIONEER 6 – American College of Cardiology (free) AND Oral semaglutide falls just short of cardioprotection in event-driven PIONEER 6 – Medicine Matters (free) AND Oral Semaglutide Meets CV Safety Mark, Reduces Events in High-Risk T2D Patients – AJMC (free)